News Medical on MSN

RAS-MAPK inhibition halts spinal deformity in neurofibromatosis type 1 mouse model

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people.
Nature

Histone deacetylase inhibitor FK228 suppresses the Ras–MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma

Histone deacetylase (HDAC) inhibitors are expected to be effective for refractory cancer because their mechanism of action differs from that of conventional antineoplastic agents. In this study, we ...
Nature

Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists

LPA and S1P: intercellular lipid mediators acting on specific GPCRs LPA and thrombin were the first GPCR agonists shown to rapidly stimulate Ras-GTP accumulation in quiescent mammalian cells (van ...
Business Wire

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
Seeking Alpha

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...
ascopubs.org

Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.

Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).